• Baicalin and Adult Visual-Cortex Plasticity

  2026-10-16

  A 2026 NeuroImage study reported that Baicalin reactivated ocular dominance plasticity and improved visual measures in adult mice with experimentally induced amblyopia. The evidence supports a role for reduced cortical inhibition, but the findings remain model-specific and do not establish clinical efficacy, a direct molecular target, or equivalence between the tested material and any commercial formulation.

• Annexin V-PE Apoptosis Kit: Scope and Evidence

  2026-10-16

  The APExBIO Annexin V-PE Apoptosis Kit (SKU K2281) is documented as a research-use fluorescence assay that detects Annexin V binding to cell-surface phosphatidylserine. Its readout can indicate a PS-associated cellular state often interpreted as an early apoptosis marker, but the available product information does not establish apoptosis specificity, quantitative performance, comparative validity, clinical utility, or identity-matched research outcomes.

• 7-dehydro Cholesterol: Identity and Evidence Limits

  2026-10-15

  APExBIO describes 7-dehydro Cholesterol, also called 7-dehydrocholesterol or 7-DHC, as an endogenous sterol intermediate linking cholesterol biosynthesis, vitamin D3 formation, and oxidative sterol biology. The product information supports a conceptual mechanism overview and defines relevant physical properties, but it does not provide identity-matched research outcomes, independent validation, or evidence for product performance in a particular model.

• Red Blood Cell Lysis Buffer: Evidence and Scope

  2026-10-15

  APExBIO’s Red Blood Cell Lysis Buffer is described as an ammonium-chloride-containing reagent for selective erythrocyte disruption in mammalian blood or tissue samples. The available material supports a cautious overview of its stated identity, mechanism, and intended measurement contexts, but provides no identity-matched study, quantitative performance data, or independent evidence for selectivity and reproducibility.

• Mithramycin A: Mechanism and Evidence Boundaries

  2026-10-14

  APExBIO describes Mithramycin A as an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions and associates this interaction with polymerase inhibition, reduced c-myc expression, and HL-60 myeloid differentiation. These claims define a plausible cancer-biology research context, but the available documentation contains no identity-matched primary study, quantitative outcomes, comparator data, or assay details. The product description therefore supports a documented identity and mechanistic framework, not an independent assessment of efficacy or experimental performance.

• XPG Mutations and the Integrated Stress Response

  2026-10-14

  A 2026 Human Genetics study compared XPG-associated XP/CS and XP cellular models and reported defects in ribosomal biogenesis, translational control, and stress signaling. The findings support a mechanistic link between altered proteostasis and Cockayne syndrome biology, while remaining limited by the cellular, mutation-specific design.

• Fenipentol and a Liver-Fibrosis Evidence Boundary

  2026-10-13

  The cited 2024 study reports that 1-phenyl-2-pentanol, identified from Moringa oleifera, reduced several fibrosis-associated markers in an activated human hepatic stellate-cell model. However, the study did not test Fenipentol, which the supplied APExBIO page identifies as 1-phenyl-1-pentanol. Its findings therefore support a preliminary, cell-based hypothesis about 1-phenyl-2-pentanol—not evidence for Fenipentol or clinical antifibrotic activity.

• Murine RNase Inhibitor: Evidence and Scope

  2026-10-13

  A source-grounded overview of the reported selectivity, oxidation-related claims, evidence strength, and applicability boundaries of Murine RNase Inhibitor, with a clear distinction between supplier information and independent biological evidence.

• Exemestane: Evidence, Context, and Limits

  2026-10-12

  Exemestane is described by APExBIO as a steroidal aromatase inhibitor intended to model cytochrome P450 aromatase inhibition and estrogen biosynthesis inhibition. However, the supplied peer-reviewed source reviews toremifene rather than exemestane, so it cannot establish exemestane-specific efficacy, safety, comparative performance, or product reproducibility.

• PXR, PCN and Urinary Concentration

  2026-10-12

  A mouse study reports that PXR activation by Pregnenolone-16α-carbonitrile is associated with increased urinary concentration through hypothalamic AVP regulation. The findings support a mechanistic PXR–AVP link, but their relevance to human water-balance disorders remains unestablished.

• DiscoveryProbe Metabolism Library: Evidence Scope

  2026-10-11

  The DiscoveryProbe™ Metabolism-related Compound Library (SKU L1032) is a supplier-described collection of 493 metabolism-related small molecules for conceptual use in metabolic enzyme, pathway, and drug-discovery research. No matched peer-reviewed paper or independent outcome data were identified, so claims about potency, selectivity, cell permeability, reproducibility, or biological performance remain vendor-level assertions.

• Nicotinamide Riboside Chloride: Research Context

  2026-10-10

  Nicotinamide Riboside Chloride (NIAGEN) is discussed here as a research compound relevant to NAD+ metabolism, metabolic dysfunction research, and neurodegenerative disease models. The overview distinguishes commercial product claims from peer-reviewed findings, including a published induced pluripotent stem cell retinal ganglion cell study that did not directly test NIAGEN. It emphasizes conceptual applications, evidence boundaries, and limitations rather than experimental procedures.

• HOXC9, Apoptosis, and ESCC Evidence

  2026-10-09

  A source-grounded overview of how HOXC9 may influence proliferation and mitochondria-dependent apoptosis in esophageal squamous cell carcinoma, with emphasis on evidence strength, conceptual Annexin V/PI applications, and the study’s clinical and methodological limitations.

• Mianserin HCl: Receptor Pharmacology and Complexes

  2026-10-09

  Mianserin HCl is more than a tetracyclic antidepressant research compound. This evidence-focused review connects 5-HT2 receptor antagonism with cyclodextrin complexation, clarifying what the available data show, where interpretation must remain cautious, and how the findings inform neuroscience receptor modulation.

• Mubritinib Enhances Cisplatin in NSCLC

  2026-10-08

  A 2022 study investigated Mubritinib (TAK 165) as a mitochondrial-active compound that can strengthen cisplatin-associated suppression of non-small cell lung cancer. The work links complex I-related mitochondrial dysfunction, reactive oxygen species accumulation, PI3K/mTOR pathway attenuation, and apoptosis, while also highlighting the limits of translating cell and xenograft findings into clinical benefit.

552 records 1/37 page Next 12345 下5页 Last page